

SUSPECT ADVERSE REACTION REPORT

I. REACTION INFORMATION

1. PATIENT INITIALS (first, last) PRIVACY	1a. COUNTRY PANAMA	2. DATE OF BIRTH Day Month Year PRIVACY	2a. AGE 62 Years	3. SEX Female	3a. WEIGHT 96.14 kg	4-6 REACTION ONSET Day Month Year 21 APR 2025	8-12 CHECK ALL APPROPRIATE TO ADVERSE REACTION <input type="checkbox"/> PATIENT DIED <input type="checkbox"/> INVOLVED OR PROLONGED INPATIENT HOSPITALISATION <input type="checkbox"/> INVOLVED PERSISTENT OR SIGNIFICANT DISABILITY OR INCAPACITY <input type="checkbox"/> LIFE THREATENING
7 + 13 DESCRIBE REACTION(S) (including relevant tests/lab data) Event Verbatim [LOWER LEVEL TERM] (Related symptoms if any separated by commas) Difficulty sleeping [Sleep disorder due to general medical condition, insomnia type] the Amgevita treatment did not have any effect. She felt as if she had not received any treatment because she no longer felt the improvement she had had in July and August 2024 [Drug effect decreased] shoulder pain/elbows hurt/Joint pain [Arthralgia] Neck pain [Neck pain] has had wind (air) in her waist/she cannot stand the pain because it is horrible and prevents her from sitting up [Gas pain] tiredness [Tiredness] (Continued on Additional Information Page)							

II. SUSPECT DRUG(S) INFORMATION

14. SUSPECT DRUG(S) (include generic name) #1) Enbrel (ETANERCEPT) Unknown #2) AMGEVITA (ADALIMUMAB) Solution for injection {Lot # 1174976; (Continued on Additional Information Page)	20. DID REACTION ABATE AFTER STOPPING DRUG? <input type="checkbox"/> YES <input type="checkbox"/> NO <input checked="" type="checkbox"/> NA
15. DAILY DOSE(S) #1) UNK #2) 40 milligra (Continued on Additional Information Page)	16. ROUTE(S) OF ADMINISTRATION #1) Unknown #2) Subcutaneous
17. INDICATION(S) FOR USE #1) Rheumatoid arthritis (Rheumatoid arthritis) #2) Arthritis rheumatoid (Rheumatoid arthritis)	21. DID REACTION REAPPEAR AFTER REINTRODUCTION? <input type="checkbox"/> YES <input type="checkbox"/> NO <input checked="" type="checkbox"/> NA
18. THERAPY DATES(from/to) #1) Unknown #2) 15-JUL-2024 / Ongoing	19. THERAPY DURATION #1) Unknown #2) Unknown

III. CONCOMITANT DRUG(S) AND HISTORY

22. CONCOMITANT DRUG(S) AND DATES OF ADMINISTRATION (exclude those used to treat reaction) #1) ARAVA (LEFLUNOMIDE) ; Unknown #2) ACTEMRA (TOCILIZUMAB) ; Unknown #3) IRBESARTAN (IRBESARTAN) ; Unknown #4) LEVOTHYROXINE (LEVOTHYROXINE) Tablet ; Unknown		
23. OTHER RELEVANT HISTORY. (e.g. diagnostics, allergies, pregnancy with last month of period, etc.) From/To Dates Type of History / Notes Description Unknown to Ongoing Relevant Med History Rheumatoid arthritis (Rheumatoid arthritis) Unknown to Ongoing Relevant Med History Fatty liver (Hepatic steatosis)		

IV. MANUFACTURER INFORMATION

24a. NAME AND ADDRESS OF MANUFACTURER Pfizer S.A. Laura Arce Mora Avenida Escazú, Torre Lexus, piso 7. Escazú San jose, COSTA RICA	26. REMARKS
24b. MFR CONTROL NO. 202500058411	25b. NAME AND ADDRESS OF REPORTER NAME AND ADDRESS WITHHELD.
24c. DATE RECEIVED BY MANUFACTURER 17-JUN-2025	24d. REPORT SOURCE <input checked="" type="checkbox"/> STUDY <input type="checkbox"/> LITERATURE <input type="checkbox"/> HEALTH PROFESSIONAL <input type="checkbox"/> OTHER:
DATE OF THIS REPORT 27-JUN-2025	25a. REPORT TYPE <input type="checkbox"/> INITIAL <input checked="" type="checkbox"/> FOLLOWUP: 3

ADDITIONAL INFORMATION**7+13. DESCRIBE REACTION(S) continued**

"lumps" or cysts in the breast [Breast cyst]

Case Description: This is a solicited report received from a Consumer or other non HCP from License Party (AMGEN). Other Case identifier(s): PA-AMGEN-PANSL2025012394 (AMGEN).

This non-serious solicited report (PANSL2025012394) was reported to Amgen on 17/JAN/2025 by a consumer from a commercial program (PSP10850) and involves a 62 year old female patient who had difficulty sleeping [PT: insomnia], the Amgevita treatment did not have any effect. She felt as if she had not received any treatment because she no longer felt the improvement she had had in July and August 2024 [PT: therapeutic product effect decreased], shoulder pain [PT: arthralgia], general pain [PT: pain], neck pain [PT: neck pain] while receiving Amgevita. No historical medical condition was reported. The patient's current medical condition included arthritis rheumatoid, fatty liver disease, osteoarthritis in her knee, affecting hair/it was falling out, affecting transaminase. The patient's concomitant medications included Leflunomide (leflunomide), Actemra (tocilizumab). The patient was suffering from fatty liver disease for 12 years. The treating physician lowered her dose of leflunomide. She was currently taking it three times a week because it was affecting her hair (i.e. it was falling out) and affecting her transaminase and liver, but with the new dose she feels well, and her hair is no longer falling out. It was effective because she works well with Amgevita. She had osteoarthritis in her knee for one year and seven months and she did not mention which one, she only mentions that she needs an operation to replace the knee. This made her feel bad. She was on the waiting list for the operation as so many mishaps have delayed the operation. She suffered from rheumatoid arthritis for 30 years. No co-suspect medications were reported. The patient began Amgevita on 15/JUL/2024. The patient mentioned that on an unknown date in SEP/2024 and OCT/2024 the Amgevita treatment did not have any effect. She felt as if she had not received any treatment because she no longer felt the improvement she had had in July and August 2024. She felt very bad, everything hurt and she refers that she had a lot of pain in her shoulders. She mentioned that it was terrible because it did not let her sleep, neither lying down, nor sitting, her elbows hurt. She spent 15 days with pain in her left shoulder, her neck hurt, her elbows hurt. The pain she had in her left shoulder, arm, forearm and the back part where the back plate was strong, because the pain made her go crazy and the pain, she felt was not even comparable to the pain of childbirth for this reason she was sleepless. From her experience she knew what it was like to feel pain and endure it. She did not take anything or medication for sleep during those 15 days. She wanted to think that the lack of effect of Amgevita was due to the fact that mentioned above (September and October) were close to the expiry date of Amgevita which was on an unknown date in NOV/2024 and that had a great influence on why the treatment was not effective in those two months. At the appointment on an unknown date in DEC/2024, she consulted him about what had happened to her with the Amgevita treatment and he told her that if she felt well and wanted to continue with Amgevita treatment, it was fine. Although she always continued to apply it and in November she felt better and even on 15/JAN/2025 she applied her dose and mentioned that she felt good (recovered). She applied 13 doses of Amgevita. She was taking Leflunomide three times a week for rheumatoid arthritis. It was a chemotherapy is tablets and it used married (together) with biologic that was put, that was Amgevita. She was taking Mapera (Actemra) subcutaneous and it was like a monotherapy because with this medicine she stopped using leflunomide because it worked well despite the fact that Mapera (Actemra) was a biological medicine. The causality analysis was performed by Asofarma Central America and Caribbean pharmacovigilance with the data received from the source document. The notifier did not provide the causal relationship between the adverse events and the medicinal product. No treatment information was received. The outcome of the events pain, insomnia, arthralgia, neck pain was reported as recovered/resolved. The outcome of the event therapeutic product effect decreased was reported as unknown. The events pain, insomnia, arthralgia, neck pain were resolved on an unknown date. Action taken with Amgevita was continued for the events pain, insomnia, arthralgia, neck pain and therapeutic product effect decreased. The causal relationship between the event therapeutic product effect and Amgevita was not provided by the other reporter. The other reporter reported that the events pain, insomnia, arthralgia, neck pain were possibly related to Amgevita. The causal relationship between the events pain, therapeutic product effect decreased, insomnia, arthralgia, neck pain and Amgevita was not provided by the consumer. No follow-up attempts are possible. No follow-up attempts are possible. No further information is expected. ADDITIONAL INFORMATION RECEIVED ON 06/MAR/2025: The patient's historical medical condition included hypertension. The patient's current medical condition included rheumatoid arthritis. The patient's historical drugs included mabthera. The patient's concomitant medications included Irbesartan (irbesartan). When she used the original MabThera (rituximab) medication, which she used for approximately 16 years, which was 100 percent of her health. Before starting Amgevita, she suffered from hypertension, for which she takes Irbesartan. The patient began Enbrel on an unknown date. It was reported that, the 25 years ago she used the medication Enbrel always to treat rheumatoid arthritis, and the Leflunomide that it was always used with some biological or biotechnological medication, in this case that he uses it with Amgevita always for the pathology. She had complied with the administration instructions, as indicated. The rheumatology nurse provided training. She did the medication require a specific intervention and/or specific training for it was use and administration. The storage temperature of the medication was in refrigerator. She keeps the medication in the refrigerator, it was away from humidity, just as it was provided, he keeps it in the refrigerator. She currently feels well and continues with the Amgevita treatment without any problem, but the treatment was not as efficient as. She always complies with the instructions and patterns of the medications, according to the package insert, since it was not the first biological medication that was to be injected. She did not consume alcoholic beverages. She did not smoke cigarettes. No treatment information was received. The causal relationship between the events pain, insomnia, arthralgia, neck pain, therapeutic product effect decreased and Enbrel was not provided by the consumer.

The reporter's assessment of the causal relationship of the events with the suspect product etanercept was not provided at the time of this report. Since no determination has been received, the case is managed based on the company causality assessment.

Amgen Causality Assessment: The events "Difficulty sleeping, Drug effect decreased, Neck pain, Pain, Shoulder pain" were assessed unrelated to etanercept.

ADDITIONAL INFORMATION**7+13. DESCRIBE REACTION(S) continued**

Enbrel is under agreement with LP Amgen.

Follow-up (22Apr2025): This is a solicited follow-up report received from a Consumer or other non HCP from License Party(Amgen). Other Case identifier(s): PA-AMGEN-PANSL2025012394 (AMGEN).

ADDITIONAL INFORMATION RECEIVED ON 22/APR/2025: The previous version event insomnia was updated to sleep disorder due to general medical condition, insomnia type. The previous version event pain was deleted in this version. The patient's surgical history included operation on ankle. The patient's current medical condition included hypertension, hypothyroidism (thyroid), chronic diverticulosis (diverticulitis), varicose veins. The patient's concomitant medications included Arava (Ileflunomide), Levothyroxine (levothyroxine). On an unknown date 2010, the patient underwent surgery on her ankle. The anaesthesiologist used an innovative preoperative methodology that caused severe damage and nearly killed her. Her consent for this method was never sought. He almost had a heart attack, as her blood pressure rose to 200 over 100. Due to this procedure performed by the anaesthesiologist, she suffered from hypertension, although it was currently under control. She had suffered from hypothyroidism (thyroid) for 26 years, and that it was currently under control. She had suffered from chronic diverticulosis (diverticulitis) for 15 years. When she was young she had many surgeries, which today due to her health do not allow her to perform a colonoscopy properly, for the condition of chronic diverticulosis (diverticulitis), to which her doctor suspects that she might develop colon cancer, this was affecting her health and had become a bit complicated for her, because to rule out the possibility of colon cancer, the proctologist indicated to her that several studies should be performed (as attached in the medical order), but one of the tests that the doctor requested was very expensive. If the results of the studies or tests are positive, they would have to operate on her and cut part of her large intestine, to prevent the development of cancer, she indicates that she had diverticula in the duodenum area of the large intestine, in addition to them that she also suffered from varicose veins. If the procedure were to be performed, she did not know how much the Amgevita treatment would change, as it was less invasive and less harmful to her health. Before starting Antgevita, she already suffered from chronic diverticulosis (diverticulitis) and varicose veins, and that these conditions had become more complicated due to age. On 15/APR/2025, she received her last application of Amgevita. On 21/APR/2025, she had wind (air) in her waist. It had been 24 hours (since experiencing air in her waist) [PT: flatulence] and that she could not stand the pain because it was horrible and prevents her from sitting up. On the day before this report (Yesterday), she felt very tired, which was why she lay down in bed. She did not provide further details. She commented that because she was sick with the pain in her waist, it took her time to walk. She hopes to recover soon from the air she had in her waist because she could not use the nonsteroidal anti-inflammatory drugs (NSAIDs) that are regularly taken with arthritis. She could not take them because they would cause bleeding in the colon, which could even lead to death. On 21/APR/2025, she took Tylenol (paracetamol) 750 milligrams at night two days. It was a pain reliever and was nothing more than Tylenol, only stronger. They normally use 500 milligrams, but these 750 milligrams was better for severe lower back pain. Her next Amgevita application was scheduled for 30/APR/2025. The outcome of the events Sleep disorder due to general medical condition, insomnia type, flatulence, fatigue was reported as not recovered/not resolved. Action taken with Amgevita was continued for the events Sleep disorder due to general medical condition, insomnia type, flatulence, fatigue. The other reporter reported that the events Sleep disorder due to general medical condition, insomnia type, flatulence, fatigue was possibly related to Amgevita. The causal relationship between the events Sleep disorder due to general medical condition, insomnia type, flatulence, fatigue and Amgevita, Enbrel was not provided by the consumer.

The reporter's assessment of the causal relationship of the events with the suspect product etanercept was not provided at the time of this report. Since no determination has been received, the case is managed based the company causality assessment.

Amgen Causality Assessment: Amgen assessed the event Arthralgia, Therapeutic product effect decreased, Neck pain, Sleep disorder due to general medical condition, insomnia type, Fatigue, Flatulence unrelated to etanercept.

Enbrel is under agreement with Amgen.

Follow-up (20May2025): This is a solicited follow-up report received from a Consumer or other non HCP from License Party(Amgen). Other Case identifier(s): PA-AMGEN-PANSL2025012394 (AMGEN).

ADDITIONAL INFORMATION RECEIVED ON 20/MAY/2025: The patient mentions that she will have a breast ultrasound on 20/MAY/2025 as recommended by the doctor, to rule out breast cancer. The mammogram showed lumps or cysts in the breast (she does not specify whether it was left or right breast) [PT: Breast cyst]. Therefore, the doctor recommended that she have an ultrasound and mammogram every 6 months. Although the patient indicates that an ultrasound and mammogram are performed annually in Panama, she mentioned that depending on the results of the ultrasound performed on 20/MAY/2025, a mammogram should be performed around the end of the year. The patient mentioned that she had not yet recovered from the pain caused by wind as she still had it. She indicated that the doctor advised her to urgently undergo blood and stool tests, which she will perform next week, to rule out colon cancer, as the patient has chronic diverticulosis, which is what causes these conditions. The patient reported that the Amgevita treatment has been effective at times, but at times it is not. The patient continued to use it but has felt somewhat ill overall from the arthritis, because she has experienced a lot of pain in her hands, fingers, elbows, and shoulders. She did not know what is happening with Amgevita because it seems to be a good medication, but then it turned out that it is no longer providing the same effect (ineffective drug). The patient stated that her most recent application was on 15/MAY/2025. No treatment information was received. The outcome of the event Breast cyst was reported as unknown. Action taken with Amgevita was continued for the event Breast cyst. The causal relationship between the events sleep disorder due to general medical condition, insomnia type, arthralgia, neck pain, therapeutic product effect decreased, flatulence, fatigue, breast cyst and Amgevita, Enbrel was not provided by the consumer.

ADDITIONAL INFORMATION

7+13. DESCRIBE REACTION(S) continued

The reporter's assessment of the causal relationship of the events with the suspect product etanercept was not provided at the time of this report. Since no determination has been received, the case is managed based the company causality assessment.

Amgen Causality Assessment: Amgen assessed the event Arthralgia, Breast cyst, Drug effect decreased, Gas pain, Neck pain, Sleep disorder due to general medical condition, insomnia type, Tiredness unrelated to etanercept.

Enbrel is under agreement with Amgen.

Follow-up (17Jun2025): This is a solicited follow-up report received from a Consumer or other non HCP from License Party(Amgen). Other Case identifier(s): PA-AMGEN-PANSL2025012394 (AMGEN).

ADDITIONAL INFORMATION RECEIVED ON 17/JUN/2025 and 18/JUN/2025: The patient began Amgevita on 15/JUL/2024. On an unknown date in 2025, The patient reports that sometimes the joint pain begins even though the treatment was applied as directed, while other times the joint pain improves when the therapy was applied. She states that her doctor was aware of this and has instructed her to continue the therapy. The outcome of the event Arthralgia was reported as not recovered/not resolved. Action taken with Amgevita was continued for the events arthralgia. The consumer reported that the event arthralgia was not related to Amgevita. The causal relationship between the event arthralgia and Enbrel was not provided by the consumer.

The reporter's assessment of the causal relationship of the events with the suspect product etanercept was not provided at the time of this report. Since no determination has been received, the case is managed based the company causality assessment.

Amgen Causality Assessment: Amgen assessed the events Breast cyst, Gas pain, Neck pain, Tiredness unrelated to etanercept and AMGEVITA. Amgen assessed the events Arthralgia, Drug effect decreased, Sleep disorder due to general medical condition, insomnia type unrelated to etanercept but related to AMGEVITA.

Enbrel is under agreement with Amgen.

Case Comment: The drug effect decreased is due to Amgevita and is unrelated to etanercept. The rest of the events are likely intercurrent or due to the natural course or progression of the disease and are unrelated to etanercept.

13. Lab Data

#	Date	Test / Assessment / Notes	Results	Normal High / Low
1		Blood pressure measurement	100	
2		Blood pressure measurement rose	200	
3	MAY-2025	Mammogram not specify whether it was left or right breast)	revealed lumps or cysts in the breast (she does	

14-19. SUSPECT DRUG(S) continued

14. SUSPECT DRUG(S) (include generic name)	15. DAILY DOSE(S); 16. ROUTE(S) OF ADMIN	17. INDICATION(S) FOR USE	18. THERAPY DATES (from/to); 19. THERAPY DURATION
#2) AMGEVITA (ADALIMUMAB) Solution for injection {Lot # 1174976; Exp.Dt. 30-SEP-2026}; Regimen #1	40 milligram, every 15 days, (40 MG 0.8 ML); Subcutaneous	Arthritis rheumatoid (Rheumatoid arthritis)	15-JUL-2024 / Ongoing; Unknown

23. OTHER RELEVANT HISTORY continued

From/To Dates	Type of History / Notes	Description
Unknown to Ongoing	Relevant Med History	Knee osteoarthritis (Osteoarthritis);
Unknown to Ongoing	Relevant Med History	Hair loss (Alopecia);
Unknown to Ongoing	Relevant Med History	Transaminases abnormal (Transaminases abnormal);
Unknown to Ongoing	Relevant Med History	Hypertension (Hypertension);
Unknown 27-Jun-2025 06:04	Past Drug Event	Mabthera (Mabthera);

ADDITIONAL INFORMATION

23. OTHER RELEVANT HISTORY continued

From/To Dates	Type of History / Notes	Description
2010 to Unknown	Relevant Med History	Ankle operation (Ankle operation);
Unknown to Ongoing	Relevant Med History	Hypothyroidism (Hypothyroidism);
Unknown to Ongoing	Relevant Med History	Diverticulitis (Diverticulitis);
Unknown to Ongoing	Relevant Med History	Varicose veins (Varicose vein);